Medical Cannabis in Palliative Care: Benefits, Risks, and Practical Considerations

According to Patient.info PatientInformationLeaflet, medical cannabis is sometimes considered as an additional treatment option for palliative care when standard approaches have not provided sufficient relief or have caused troublesome side effects.

Medical cannabis brings a new set of tools to a field that already relies on opioids, anti‑emetics, and anxiolytics. Understanding how it works, where it fits, and what could go wrong helps patients and clinicians decide whether the trade‑off of adding a cannabinoid‑based product is worthwhile.

The Endocannabinoid System and How Cannabis Interacts

The body naturally produces chemicals called endocannabinoids. These bind to receptors spread throughout the brain, nervous system, and immune system – a network known as the endocannabinoid system (ECS). The ECS helps regulate pain perception, nausea, appetite, sleep, mood, and immune responses. Cannabis‑derived compounds called cannabinoids mimic endocannabinoids, activating the same receptors. Two cannabinoids dominate medical use:

• Cannabidiol (CBD) – does not produce a psycho‑active “high” and is thought to reduce anxiety, improve sleep, and modulate pain.
• Tetrahydrocannabinol (THC) – produces psycho‑active effects, can stimulate appetite, and may relieve pain, nausea, and sleep disturbance.

Research is still clarifying the exact pathways, but the basic idea is that adding external cannabinoids can boost a system that may be under‑active in advanced illness. Because the ECS is involved in many symptom domains, a single product can potentially touch pain, nausea, appetite, and sleep at once.

Where Cannabis Fits Among Existing Palliative Medicines

Traditional palliative regimens rely on:

• Opioids for severe nociceptive pain.
• Anticonvulsants or antidepressants for neuropathic pain.
• 5‑HT₃ antagonists and NK‑1 blockers for chemotherapy‑induced nausea.
• Steroids or pro‑kinetic agents for appetite loss.
• Benzodiazepines for anxiety and sleep.

Medical cannabis is usually introduced after these first‑line agents have failed to provide adequate relief or have caused intolerable side effects. In practice this means a patient might already be on an opioid regimen, a anti‑emetic, and a sleep aid before a specialist adds a CBD‑dominant oil for anxiety or a THC‑rich capsule for appetite. The key trade‑off is adding a drug that can interact with the ECS while also bringing its own side‑effect profile, such as sedation or, paradoxically, anxiety.

Formulation Options: Choosing the Right Delivery Method

Cannabis can be administered in many ways, each with its own onset, duration, and practicality. Below is a comparison of the most common forms mentioned in the source.

The choice often balances speed of relief (inhaled forms) against convenience and side‑effect tolerance (oral forms). For patients with swallowing problems, a suppository or pessary may be the only viable route.

Benefits Reported in Real‑World Use

The source lists several symptom areas where patients have reported improvement:

• Neuropathic pain – especially when opioids fall short.
• Nausea and vomiting – cannabinoids have a long history of anti‑emetic use, and some studies show benefit after standard anti‑sickness drugs fail.
• Appetite stimulation – THC‑rich products can increase food intake in some individuals.
• Sleep quality – many patients notice faster sleep onset and longer uninterrupted sleep.
• Anxiety reduction – CBD‑dominant formulations tend to calm without causing a “high”.

Improvement is often modest on any single symptom score, but patients frequently describe a cumulative uplift in quality of life: better sleep leads to more energy, which improves mood and the ability to engage with family.

Who Gains and Who Might Lose

Potential beneficiaries include:

• Patients with refractory neuropathic pain who cannot increase opioid doses.
• Those experiencing chemotherapy‑induced nausea despite anti‑emetics.
• Individuals whose appetite has plummeted and who are losing weight.
• Patients whose sleep is fragmented and who have tried multiple hypnotics.

Potential losers or at‑risk groups:

• People with a history of severe anxiety or psychosis, where THC could exacerbate symptoms.
• Individuals already on high‑dose sedatives, because additive sleepiness raises fall risk.
• Patients prone to cannabinoid hyperemesis syndrome (CHS), a rare condition causing severe vomiting after chronic heavy use.
• Those who drive for work or need fine motor coordination; even low‑level impairment may make operating machinery unsafe.

The trade‑off is therefore context‑specific: the same THC that boosts appetite could also impair cognition. Clinicians must weigh each patient’s symptom burden against their functional priorities.

What Could Go Wrong or Remain Unclear

The source highlights several uncertainties and risks:

• Limited evidence base – most studies are small, open‑label, or rely on patient‑reported outcomes. Long‑term safety data, especially for inhaled forms, are sparse.
• Variable response – some patients feel no benefit, while others experience strong effects. Predictors of response are not well defined.
• Side‑effects – higher THC doses can cause dizziness, dry mouth, and in rare cases, CHS. CBD is generally well tolerated but can interact with liver‑metabolizing enzymes, affecting other drugs.
• Regulatory constraints – only specialist doctors can prescribe CBMPs in the UK; access may be limited by geography or waiting lists.
• Driving and occupational safety – even a mild “high” can render a patient unfit for driving, and the legal guidance varies by individual tolerance.
• Potential dependence – prolonged high‑THC use can lead to physiological dependence, though the risk is lower under medical supervision.

Because many of these issues are not fully resolved, ongoing monitoring, dose titration, and clear communication about expectations are essential.

Practical Steps for Patients and Clinicians

1. Start low, go slow – begin with a low‑dose CBD‑dominant product and increase gradually under supervision.
2. Choose the route that matches the symptom – rapid‑onset inhaled forms for breakthrough pain, oral oils for steady‑state sleep aid.
3. Monitor side‑effects daily – keep a simple log of pain scores, nausea episodes, sleep quality, and any adverse sensations.
4. Adjust timing – taking the dose in the evening can reduce daytime drowsiness; splitting the dose may smooth peaks and troughs.
5. Plan for emergencies – know when to contact the healthcare team if severe nausea, vomiting, or anxiety emerges.
6. Review driving status – discuss any impairment with the clinician before operating a vehicle or machinery.

By following these steps, the addition of medical cannabis becomes a managed component of a broader palliative strategy rather than a stand‑alone solution.

Sources

• Patient.info PatientInformationLeaflet – Medical cannabis in palliative care